- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Biogen Idec Inc
+ Add to WatchlistBIIB:US
235.2400 USD 2.6200 1.13%
Share
As of 17:20:00 ET on 05/24/2013.
More on BIIB
News for Biogen Idec Inc (BIIB)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Alex Denner Joins Vivus Activist Slate in Post-Icahn Move
- MS Patients Choose Death Risk With Potent Drug Treatment
- Elan Board Unanimously Rejects $6.4 Billion Takeover Offer
- Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’
- Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash
- Roche Experimental Leukemia Drug Helps Shrink Tumors
- Biogen MS Pill’s Early Sales May Help It Beat Estimates
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Biogen Raises 2013 Forecast After First-Quarter Profit Surges
- Biogen Profit Beats Estimates on Tysabri Revenue Increase
- Psoriasis Drug Like Biogen’s BG-12 Linked to Brain Disease
- Boom or Bust: BioGen, Ralph Lauren, Caterpillar
- Elan Board Rejects Royalty Pharma Takeover Bid as Too Low
- Boston Is Locked Down With City Frozen From Tufts to Trains
- Elan Says Buyback Tender Strike Price Set at $11.25 per ADR
- IRSH: Elan Corporation PLC: Elan Announces Pricing of US$850 Million in Aggregate Principal Amount of Senior Notes Due 2021 Published 17 hours ago
- Elan Announces Pricing of US$850 Million in Aggregate Principal Amount of Senior Notes Due 2021 Published May 23, 2013
- Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer Published May 23, 2013
- Biogen Idec to Present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference Published May 22, 2013
- Portola Announces Pricing of Initial Public Offering Published May 22, 2013
- RBCC Opens Talks to Acquire Tech Innovators in $142 Billion Drug Delivery Market Published May 21, 2013
- Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis Published May 21, 2013
- IRSH: Elan Corporation PLC: Elan Announces Proposed Offering of US$800.0 Million in Aggregate Principal Amount of Senior Notes Published May 20, 2013
- Elan Announces Proposed Offering of US$800.0 Million in Aggregate Principal Amount of Senior Notes Due 2021 Published May 20, 2013
- FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A Published May 13, 2013
- RBCC Partner n3D Signs U.S. Distribution Agreement Published May 13, 2013
- Isis Pharmaceuticals Earns $3.5 Million from Biogen Idec Published May 09, 2013
- Portola Announces Its Factor Xa Inhibitor Antidote PRT4445 Produces Rapid, Sustained and Dose-Related Reversal of the Published May 08, 2013
- The Zacks Analyst Blog Highlights: Bayer, Biogen Idec, Conceptus, Microsoft and J. C. Penney Published May 07, 2013
- World’s Premiere Science Journal Touts Revolutionary Innovations by RBCC Partner Nano3D Published May 06, 2013
- Alex Denner Joins Vivus Activist Slate in Post-Icahn Move
- Novartis Ramps Up Alzheimer’s Drug Pursuit as Rivals Fail
- Hedge Funds Trail S&P 500 by 10 Percentage Points, Goldman Says
- Addex Rises on Positive Rodent Experiment Results: Zurich Mover
- Novartis Sees MorphoSys Muscle-Atrophy Drug as Exciting
- U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancer
- Largest Weekly Option Sentiment Changes for S&P 500 Companies
- SAC Digs In as Deadline Nears for U.S. Insider Cases
- Japan Biotech Firms Jump as Abenomics Cash Spurs Speculation
- Puma Biotech Gains After Rival Drug Data Show No Threat
- Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine
- Billionaire Frost Props Up Prolor Bid With Stock Buys
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Gene-Testing Dispute Focuses on How Much a Patient Should Know
- Tennis With Evert, Baseball With Microsoft: D.C. Scene
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page